Education
About Us
Working with TipRanks
Follow Us
BioInvent International AB (SE:BINV)
:BINV
Earnings Data
Report Date
Feb 26, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
―Last Year’s EPS
-1.78Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call showcased BioInvent's strategic focus on its lead programs, resulting in positive clinical outcomes and increased sales for the nine-month period. However, the quarter saw decreased sales and increased operating costs, leading to negative financial results.Company Guidance
Portfolio Prioritization and Phase IIa Trials Initiation
BioInvent has prioritized its portfolio to focus on two lead programs, BI-1808 and BI-1206, with BI-1206 starting a Phase IIa trial in advanced or metastatic non-small cell lung cancer and uveal melanoma.
Positive Clinical Data and Milestones
BI-1808 demonstrated 100% disease control in CTCL and PTCL with promising efficacy and mild adverse events. BI-1206 showed 100% disease control in the first 8 patients in non-Hodgkin lymphoma, with a good overall response rate.
Increased Net Sales for January to September 2025
Net sales for January to September 2025 were SEK 223 million, a significant increase from SEK 23 million in the same period of 2024, mainly due to a $20 million payment from XOMA Royalty.
Financial Stability
Liquid funds and investments amounted to SEK 690 million, with financing secured into Q1 2027.
SE:BINV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:BINV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 29, 2025 | kr27.30 | kr31.10 | +13.92% |
Aug 26, 2025 | kr36.15 | kr33.25 | -8.02% |
Apr 29, 2025 | kr29.30 | kr30.90 | +5.46% |
Feb 27, 2025 | kr24.45 | kr25.40 | +3.89% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioInvent International AB (SE:BINV) report earnings?
BioInvent International AB (SE:BINV) is schdueled to report earning on Feb 26, 2026, Before Open (Confirmed).
What is BioInvent International AB (SE:BINV) earnings time?
BioInvent International AB (SE:BINV) earnings time is at Feb 26, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of BioInvent International AB stock?
The P/E ratio of BioInvent International AB is N/A.
What is SE:BINV EPS forecast?
Currently, no data Available